Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan;30(1):e5.
doi: 10.1136/ejhpharm-2021-003018. Epub 2021 Sep 14.

Advanced ALK-positive lung cancer with lorlatinib versus crizotinib in Asian patients with brain metastases

Hung Shih-Chang  1
Affiliations
Comment

Advanced ALK-positive lung cancer with lorlatinib versus crizotinib in Asian patients with brain metastases

Hung Shih-Chang. Eur J Hosp Pharm. 2023 Jan.
No abstract available

Keywords: chemistry; clinical; medical oncology; pharmaceutical; pulmonary medicine; research design.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
    Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.

References

    1. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020;383:2018–29. 10.1056/NEJMoa2027187 - DOI - PubMed
    1. Bauer TM, Shaw AT, Johnson ML, et al. Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. Target Oncol 2020;15:55–65. 10.1007/s11523-020-00702-4 - DOI - PMC - PubMed
    1. Chen W, Jin D, Shi Y, et al. The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain. Cancer Med 2020;9:4350–9. 10.1002/cam4.3061 - DOI - PMC - PubMed
    1. Wang SV, Jin Y, Fireman B, et al. Relative performance of propensity score matching strategies for subgroup analyses. Am J Epidemiol 2018;187:1799–807. 10.1093/aje/kwy049 - DOI - PubMed